绥美凯治疗艾滋病的效果怎样呢？

It is a compound preparation, each tablet contains dolutegravir sodium (calculated as dolutegravir) 50 mg, abacavir sulfate (calculated as abacavir 600 mg) and lamivudine 300 mg, suitable for the treatment of adults infected with human immunodeficiency virus (HIV) and adolescents over 12 years old (weight at least 40 kg) Among them, Doslavir can inhibit HIV integrase through the strand transfer step (a key step in the HIV replication cycle), which binds to the active site of the integrase and blocks the integration of reverse transcribed DNA (DNA). Today we will learn about the effect of Suimeikan in treating AIDS.

For adults and adolescents, the recommended dosage is one tablet of Suimex, once daily. Adults or adolescents who weigh less than 40 kg should not take this product as this product is a fixed-dose tablet and cannot be reduced. Trimax is a fixed-dose tablet and cannot be used in patients who require dose adjustments. If discontinuation of one of the active ingredients or dose adjustment is necessary, separate formulations of dolavir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the product information for these drugs.  

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in Trimeq is significantly less than that of the other two drugs, making it less likely to develop drug resistance. In the real world, antiviral treatment-naïve patients treated with DTG have a lower proportion of central nervous system-related (CNS) adverse events than the four drugs RAL (Ascent), DRV/r (darunavir), EFV (efavirenz) and ATV/r (atazanavir). Therefore, the drug safety of Suimeike, which is based on DTG integrase inhibitors, has proven to be controllable.

In general, Suimeikai has four main advantages: 1. Excellent efficacy and significant virus suppression effect; 2. The three drugs are equivalent, and both newly-treated and previously treated patients have high drug resistance barriers, which is not easy to lead to drug resistance; 3. It is easy to take, only needs to be taken once a day, and there is no need to consider food effects; 4. The drug has low side effects and good tolerance, and the discontinuation rate due to drug side effects is low; 5. There are few interactions between metabolic pathways and other drugs.

The above is the content of the effect, I hope it can help you!